GlassScriptPhysician profile
Sonia Sharma
NPI 1043577794
$7,595.29
in general payments reported to CMS, 2019-2025
43 companies · $1,538 in 2025
The $1,538 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $147 · 2021: $1,413 · 2022: $1,579 · 2023: $1,510 · 2024: $1,409 · 2025: $1,538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,452 · Education: $4.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,452.35 |
| Education | $4.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $924.48 | 2021-2025 | |
| Lilly USA, LLC | $817.92 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Dexcom, INC. | $679.68 | 2020-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $637.67 | 2020-2025 | |
| Tandem Diabetes Care, INC. | $438.03 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Novo Nordisk INC | $425.44 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $351.89 | 2021-2025 | Korlym |
| Abbvie INC. | $280.05 | 2021-2025 | Synthroid |
| Amgen INC. | $254.89 | 2021-2025 | Evenity, Prolia, Tepezza |
| Xeris Pharmaceuticals, INC. | $225.82 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Alexion Pharmaceuticals, INC. | $220.94 | 2021-2024 | Strensiq |
| Recordati_rare_diseases_inc. | $182.68 | 2022-2025 | Isturisa, Signifor Lar |
| Nevro Corp. | $181.07 | 2022-2024 | Senza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.31 | 2021-2024 | Jardiance, Synjardy |
| Radius Health, INC. | $155.04 | 2022-2024 | Tymlos |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $150.97 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Amneal Pharmaceuticals LLC | $132.47 | 2021-2025 | Unithroid |
| Merck Sharp & Dohme LLC | $125.60 | 2020-2022 | |
| Insulet Corporation | $123.79 | 2021-2025 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $120.71 | 2021-2023 | Farxiga |
| Almatica Pharma LLC | $108.94 | 2024-2025 | Teriparatide |
| Ascendis Pharma Endocrinology INC | $99.36 | 2025 | Yorvipath |
| Beta Bionics, INC. | $86.08 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Ibsa Pharma INC. | $84.44 | 2020-2025 | Licart, Tirosint, Flector |
| Antares Pharma, INC. | $60.62 | 2022-2024 | Xyosted |
| Ultragenyx Pharmaceutical INC. | $60.29 | 2021-2024 | Crysvita |
| Medtronic, INC. | $59.46 | 2021-2024 | Minimed 780g |
| Grt US Holding, INC. | $51.47 | 2021-2022 | |
| Pfizer INC. | $48.93 | 2022-2023 | |
| Kyowa Kirin, INC. | $48.22 | 2023-2024 | Crysvita |
| Sequel Med Tech, LLC | $38.02 | 2025 | Twiist |
| Clarus Therapeutics INC. | $30.41 | 2021 | |
| Neurocrine Biosciences, INC. | $25.35 | 2025 | |
| Sandoz INC. | $25.21 | 2025 | Jubbonti |
| Eusa Pharma (US) LLC | $25.01 | 2022 | |
| Averitas Pharma INC. | $21.68 | 2023 | Qutenza |
| Medtronic Minimed, INC. | $20.74 | 2020 | |
| Horizon Therapeutics Plc | $18.52 | 2021 | |
| Lifescan, INC. | $17.86 | 2022 | |
| Esperion Therapeutics, INC. | $17.70 | 2022 | |
| Cequr Corporation | $17.57 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.55 | 2025 | |
| Acella Pharmaceuticals, LLC | $15.41 | 2025 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonia Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.